Abbott Licenses Neurocrine Drug | June 21, 2010 Issue - Vol. 88 Issue 25 | Chemical & Engineering News
Volume 88 Issue 25 | p. 17 | Concentrates
Issue Date: June 21, 2010

Abbott Licenses Neurocrine Drug

Department: Business
Keywords: Abbott, Neurocrine Biosciences, endometriosis

Abbott Laboratories will pay $75 million up front for access to Neurocrine Biosciences’ elagolix, which has completed Phase II trials to treat endometriosis. The San Diego-based biotechnology company could get up to $500 million more if elagolix hits certain clinical and commercial milestones. Elagolix blocks gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, lowering the levels of sex hormones in circulation. The drug candidate differs from currently marketed drugs, which are peptides that act as GnRH agonists, in that it only partially suppresses estrogen and thus prevents the bone loss associated with other drugs.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment